Thrombospondin-1: A unique marker to identify in vitro platelet activation when monitoring in vivo processes

Journal of Thrombosis and Haemostasis

Volumn 8, Issue 8, 2010, Pages 1809-1819

  Starlinger, P ^a   Moll, H P ^a   Assinger, A ^b   Nemeth, C ^a   Hoetzenecker, K ^a   Gruenberger, B ^c   Gruenberger, T ^a   Kuehrer, I ^a   Schoppmann, S F ^a   Gnant, M ^a   Brostjan, C ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

Author keywords

Cancer; Marker; Platelet activation; Thrombospondin 1; Wound healing

Indexed keywords

BEVACIZUMAB; CAPECITABINE; GEMCITABINE; OXALIPLATIN; THROMBOSPONDIN 1;

ADD ON THERAPY; ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BLOOD SAMPLING; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DEGRANULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; IN VIVO STUDY; MALE; MOLECULAR STABILITY; MULTIPLE CYCLE TREATMENT; PANCREAS CANCER; PARAMETER; PRIORITY JOURNAL; PROTEIN ANALYSIS; REFERENCE VALUE; SENSITIVITY ANALYSIS; SIDE EFFECT; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; WOUND HEALING;

ADULT; AGED; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PLATELET ACTIVATION; PROTEIN ISOFORMS; RECOMBINANT PROTEINS; TEMPERATURE; THROMBOSPONDIN 1; TIME FACTORS; WOUND HEALING;

EID: 77958562198     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2010.03908.x     Document Type: Article

References (35)

1. Kamath S, Blann AD, Lip GY. Platelet activation: assessment and quantification. Eur Heart J 2001, 22:1561-71.
2. White JG. Platelets and atherosclerosis. Eur J Clin Invest 1994, 24(Suppl. 1):25-9.
3. Falk E, Fernandez-Ortiz A. Role of thrombosis in atherosclerosis and its complications. Am J Cardiol 1995, 75:3B-11B.
4. Minamino T, Kitakaze M, Asanuma H, Ueda Y, Koretsune Y, Kuzuya T, Hori M. Plasma adenosine levels and platelet activation in patients with atrial fibrillation. Am J Cardiol 1999, 83:194-8.
5. Ferroni P, Roselli M, Martini F, D'Alessandro R, Mariotti S, Basili S, Spila A, Aloe S, Palmirotta R, Maggini A, Del Monte G, Mancini R, Graziano F, Cosimelli M, Guadagni F. Prognostic value of soluble P-selectin levels in colorectal cancer. Int J Cancer 2004, 111:404-8.
6. Gurney D, Lip GY, Blann AD. A reliable plasma marker of platelet activation: does it exist? Am J Hematol 2002, 70:139-44.
7. Ivandic BT, Spanuth E, Haase D, Lestin HG, Katus HA. Increased plasma concentrations of soluble CD40 ligand in acute coronary syndrome depend on in vitro platelet activation. Clin Chem 2007, 53:1231-4.
8. Weber M, Rabenau B, Stanisch M, Elsaesser A, Mitrovic V, Heeschen C, Hamm C. Influence of sample type and storage conditions on soluble CD40 ligand assessment. Clin Chem 2006, 52:888-91.
9. Kaplan KL, Owen J. Plasma levels of beta-thromboglobulin and platelet factor 4 as indices of platelet activation in vivo. Blood 1981, 57:199-202.
10. Abbasciano V, Tassinari D, Sartori S, Trevisani L, Arcudi D, Bianchi MP, Liboni A. Usefulness of coagulation markers in staging of gastric cancer. Cancer Detect Prev 1995, 19:331-6.
11. Tamagawa-Mineoka R, Katoh N, Ueda E, Masuda K, Kishimoto S. Elevated platelet activation in patients with atopic dermatitis and psoriasis: increased plasma levels of beta-thromboglobulin and platelet factor 4. Allergol Int 2008, 57:391-6.
12. Cella G, Scattolo N, Cappellato MG, Girolami A, Strauss WE, Sasahara AA. Platelet factor 4 release induced by intravenous administration of heparin. Folia Haematol Int Mag Klin Morphol Blutforsch 1985, 112:165-74.
13. Voit S, Udelhoven M, Lill G, Aktas B, Nieswandt B, Schror K, Weber AA. The C-terminal peptide of thrombospondin-1 stimulates distinct signaling pathways but induces an activation-independent agglutination of platelets and other cells. FEBS Lett 2003, 544:240-5.
14. Leung LL. Role of thrombospondin in platelet aggregation. J Clin Invest 1984, 74:1764-72.
15. Leung LL, Nachman RL. Complex formation of platelet thrombospondin with fibrinogen. J Clin Invest 1982, 70:542-9.
16. Xie L, Chesterman CN, Hogg PJ. Control of von Willebrand factor multimer size by thrombospondin-1. J Exp Med 2001, 193:1341-9.
17. Isenberg JS, Romeo MJ, Yu C, Yu CK, Nghiem K, Monsale J, Rick ME, Wink DA, Frazier WA, Roberts DD. Thrombospondin-1 stimulates platelet aggregation by blocking the antithrombotic activity of nitric oxide/cGMP signaling. Blood 2008, 111:613-23.
18. Baenziger NL, Brodie GN, Majerus PW. Isolation and properties of a thrombin-sensitive protein of human platelets. J Biol Chem 1972, 247:2723-31.
19. Bonnefoy A, Moura R, Hoylaerts MF. The evolving role of thrombospondin-1 in hemostasis and vascular biology. Cell Mol Life Sci 2008, 65:713-27.
20. Adams JC, Bentley AA, Kvansakul M, Hatherley D, Hohenester E. Extracellular matrix retention of thrombospondin 1 is controlled by its conserved C-terminal region. J Cell Sci 2008, 121:784-95.
21. Dardik R, Lahav J. Functional changes in the conformation of thrombospondin-1 during complexation with fibronectin or heparin. Exp Cell Res 1999, 248:407-14.
22. Rabhi-Sabile S, Pidard D, Lawler J, Renesto P, Chignard M, Legrand C. Proteolysis of thrombospondin during cathepsin-G-induced platelet aggregation: functional role of the 165-kDa carboxy-terminal fragment. FEBS Lett 1996, 386:82-6.
23. Bonnefoy A, Legrand C. Proteolysis of subendothelial adhesive glycoproteins (fibronectin, thrombospondin, and von Willebrand factor) by plasmin, leukocyte cathepsin G, and elastase. Thromb Res 2000, 98:323-32.
24. Mikhailenko I, Krylov D, Argraves KM, Roberts DD, Liau G, Strickland DK. Cellular internalization and degradation of thrombospondin-1 is mediated by the amino-terminal heparin binding domain (HBD). High affinity interaction of dimeric HBD with the low density lipoprotein receptor-related protein. J Biol Chem 1997, 272:6784-91.
25. Dawes J, Clemetson KJ, Gogstad GO, McGregor J, Clezardin P, Prowse CV, Pepper DS. A radioimmunoassay for thrombospondin, used in a comparative study of thrombospondin, beta-thromboglobulin and platelet factor 4 in healthy volunteers. Thromb Res 1983, 29:569-81.
26. Zellner M, Winkler W, Hayden H, Diestinger M, Eliasen M, Gesslbauer B, Miller I, Chang M, Kungl A, Roth E, Oehler R. Quantitative validation of different protein precipitation methods in proteome analysis of blood platelets. Electrophoresis 2005, 26:2481-9.
27. Assinger A, Schmid W, Eder S, Schmid D, Koller E, Volf I. Oxidation by hypochlorite converts protective HDL into a potent platelet agonist. FEBS Lett 2008, 582:778-84.
28. Bergseth G, Lappegard KT, Videm V, Mollnes TE. A novel enzyme immunoassay for plasma thrombospondin. Comparison with beta-thromboglobulin as platelet activation marker in vitro and in vivo. Thromb Res 2000, 99:41-50.
29. Ohkawa R, Hirowatari Y, Nakamura K, Ohkubo S, Ikeda H, Okada M, Tozuka M, Nakahara K, Yatomi Y. Platelet release of beta-thromboglobulin and platelet factor 4 and serotonin in plasma samples. Clin Biochem 2005, 38:1023-6.
30. Singer AJ, Clark RA. Cutaneous wound healing. N Engl J Med 1999, 341:738-46.
31. Boneu B, Bugat R, Boneu A, Eche N, Sie P, Combes PF. Exhausted platelets in patients with malignant solid tumors without evidence of active consumption coagulopathy. Eur J Cancer Clin Oncol 1984, 20:899-903.
32. Nash GF, Turner LF, Scully MF, Kakkar AK. Platelets and cancer. Lancet Oncol 2002, 3:425-30.
33. Ay C, Simanek R, Vormittag R, Dunkler D, Alguel G, Koder S, Kornek G, Marosi C, Wagner O, Zielinski C, Pabinger I. High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). Blood 2008, 112:2703-8.
34. Iruela-Arispe ML, Lombardo M, Krutzsch HC, Lawler J, Roberts DD. Inhibition of angiogenesis by thrombospondin-1 is mediated by 2 independent regions within the type 1 repeats. Circulation 1999, 100:1423-31.
35. Al-Mondhiry H. Beta-thromboglobulin and platelet-factor 4 in patients with cancer: correlation with the stage of disease and the effect of chemotherapy. Am J Hematol 1983, 14:105-11.